NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.09 -0.32 (-3.80 %)
(As of 11/14/2018 04:00 PM ET)
Previous Close$8.41
Today's Range$7.96 - $8.58
52-Week Range$7.42 - $13.97
Volume352,843 shs
Average Volume426,400 shs
Market Capitalization$887.66 million
P/E Ratio-6.37
Dividend YieldN/A
Beta0.73
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Receive LXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LXRX
Previous SymbolNASDAQ:LEXG
CUSIP52887210
Phone281-863-3000

Debt

Debt-to-Equity Ratio8.85
Current Ratio2.90
Quick Ratio2.83

Price-To-Earnings

Trailing P/E Ratio-6.37
Forward P/E Ratio-6.27
P/E GrowthN/A

Sales & Book Value

Annual Sales$90.33 million
Price / Sales9.49
Cash FlowN/A
Price / CashN/A
Book Value($0.28) per share
Price / Book-28.89

Profitability

EPS (Most Recent Fiscal Year)($1.27)
Net Income$-129,050,000.00
Net Margins-168.23%
Return on Equity-1,247.65%
Return on Assets-37.28%

Miscellaneous

Employees174
Outstanding Shares105,930,000
Market Cap$887.66 million
OptionableOptionable

Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.33) by $0.07. The biopharmaceutical company had revenue of $6.90 million for the quarter, compared to analysts' expectations of $12.56 million. Lexicon Pharmaceuticals had a negative net margin of 168.23% and a negative return on equity of 1,247.65%. The business's quarterly revenue was down 74.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.29) EPS. View Lexicon Pharmaceuticals' Earnings History.

When is Lexicon Pharmaceuticals' next earnings date?

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Lexicon Pharmaceuticals.

What price target have analysts set for LXRX?

7 brokers have issued twelve-month price objectives for Lexicon Pharmaceuticals' stock. Their forecasts range from $10.00 to $42.00. On average, they anticipate Lexicon Pharmaceuticals' stock price to reach $25.25 in the next twelve months. This suggests a possible upside of 212.1% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.

What is the consensus analysts' recommendation for Lexicon Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals.

What are Wall Street analysts saying about Lexicon Pharmaceuticals stock?

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (11/7/2018)
  • 2. Needham & Company LLC analysts commented, "Lexicon presented additional data from sotagliflozin Phase 3 program in at ADA mtg and published full 52wk data from both inTANDEM1 and inTANDEM2 trials. We spoke w/ mgmt for an update. Overall sotagliflozin safety/ efficacy profile is unch and we continue to believe the drug will have a role in T1D treatment. Additional data from dapagliflozin program in T1D were also presented (AstraZeneca/ BMS). Sotagliflozin may have modest benefits as a dual SGLT1/2 inhibitor over single SGLT2 inhibition, but it is still a challenge to compare the drugs across different trials. Maintain HOLD due to slow Xermelo launch and our expectation that Phase 3 T2D next year will help clarify potential overall advantages of sotagliflozin over SGLT2 inhibitors." (6/25/2018)

Has Lexicon Pharmaceuticals been receiving favorable news coverage?

News stories about LXRX stock have been trending positive recently, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Lexicon Pharmaceuticals' key competitors?

Who are Lexicon Pharmaceuticals' key executives?

Lexicon Pharmaceuticals' management team includes the folowing people:
  • Mr. Lonnel Coats, Pres, CEO & Director (Age 53)
  • Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 53)
  • Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 55)
  • Dr. Praveen Tyle, Exec. VP of R&D (Age 58)
  • Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 59)

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.64%), BlackRock Inc. (4.16%), Pinnacle Associates Ltd. (0.55%), Candriam Luxembourg S.C.A. (0.48%), Teachers Retirement System of The State of Kentucky (0.30%) and Pictet Asset Management Ltd. (0.25%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Which institutional investors are selling Lexicon Pharmaceuticals stock?

LXRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Teachers Retirement System of The State of Kentucky, Pinnacle Associates Ltd., Credit Suisse AG, Wedbush Securities Inc., Pictet Asset Management Ltd. and BlackRock Inc.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Which institutional investors are buying Lexicon Pharmaceuticals stock?

LXRX stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Candriam Luxembourg S.C.A., Bank of Montreal Can, Tekla Capital Management LLC and GSA Capital Partners LLP. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $8.09.

How big of a company is Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals has a market capitalization of $887.66 million and generates $90.33 million in revenue each year. The biopharmaceutical company earns $-129,050,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Lexicon Pharmaceuticals employs 174 workers across the globe.

What is Lexicon Pharmaceuticals' official website?

The official website for Lexicon Pharmaceuticals is http://www.lexpharma.com.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.


MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  289 (Vote Underperform)
Total Votes:  613
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel